Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2002 8
2003 16
2004 21
2005 30
2006 34
2007 51
2008 48
2009 73
2010 115
2011 112
2012 170
2013 203
2014 213
2015 240
2016 269
2017 293
2018 333
2019 374
2020 436
2021 515
2022 382
Text availability
Article attribute
Article type
Publication date

Search Results

3,500 results
Results by year
Filters applied: . Clear all
Page 1
FBXL2 counteracts Grp94 to destabilize EGFR and inhibit EGFR-driven NSCLC growth.
Niu M, Xu J, Liu Y, Li Y, He T, Ding L, He Y, Yi Y, Li F, Guo R, Gao Y, Li R, Li L, Fu M, Hu Q, Luo Y, Zhang C, Qin K, Yi J, Yu S, Yang J, Chen H, Wang L, Li Z, Dong B, Qi S, Ouyang L, Zhang Y, Cao Y, Xiao ZJ. Niu M, et al. Among authors: wang l. Nat Commun. 2021 Oct 11;12(1):5919. doi: 10.1038/s41467-021-26222-x. Nat Commun. 2021. PMID: 34635651 Free PMC article.
Immune-Mediated Diseases Associated With Cancer Risks.
He MM, Lo CH, Wang K, Polychronidis G, Wang L, Zhong R, Knudsen MD, Fang Z, Song M. He MM, et al. Among authors: wang l. JAMA Oncol. 2022 Feb 1;8(2):209-219. doi: 10.1001/jamaoncol.2021.5680. JAMA Oncol. 2022. PMID: 34854871 Free PMC article.
3,500 results